Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
Ibritumomab tiuxetan (Zevalin®) has not been endorsed for use within NHS Wales for the treatment of adult patients with rituximab relapsed or refractory CD20+ follicular B-cell non-Hodgkin's lymphoma (NHL). The holder of the marketing authorisation is not in a position to progress a submission to AWMSG for the appraisal of ibritumomab tiuxetan (Zevalin®) for the above indication. As a result, AWMSG cannot provide advice to the Minister for Health and Social Services. |
||
|
||
Medicine details |
||
| Medicine name | ibritumomab tiuxetan (Zevalin®) | |
| Formulation | 1.6 mg/ml radiopharmaceutical preparations for infusion | |
| Reference number | 158 | |
| Indication | Treatment of adult patients with rituximab relapsed or refractory CD20+ follicular B-cell non-Hodgkin's lymphoma (NHL). |
|
| Company | Bayer Healthcare Pharmaceuticals | |
| BNF chapter | Malignant disease & immunosuppression | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 18/05/2009 | |